CD274 and cervical carcinoma: Currently, the use of pembrolizumab as first-line chemotherapy for recurrent cervical cancer is confined to patients with PD-L1 positivity (Combined Positive Score, CPS≥1), but the therapeutic results have not been satisfactory.